Zydus Lifesciences nears US oncology acquisition for up to 150 million to expand cancer distribution

The catch is how it plans to sell cancer drugs

Zydus Lifesciences is reportedly close to buying a US oncology drug maker in a deal valued at $100 to $150 million. The acquisition is expected to help the Indian company build its own distribution network for anti-cancer drugs in the US, while also bringing along the target’s biologic drug pipeline. A deal is expected soon.